Wellbutrin Retard Tafla með breyttan losunarhraða 300 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

wellbutrin retard tafla með breyttan losunarhraða 300 mg

glaxosmithkline pharma a/s - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 300 mg

Bekemv Evrópusambandið - íslenska - EMA (European Medicines Agency)

bekemv

amgen technology (ireland) uc - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5.

Omvoh Evrópusambandið - íslenska - EMA (European Medicines Agency)

omvoh

eli lilly nederland b.v. - mirikizumab - ristilbólga, þvagsýrugigt - Ónæmisbælandi lyf - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.

Abrysvo Evrópusambandið - íslenska - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - sýkingar af völdum sýklalyfja - bóluefni - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. sjá kafla 4. 2 og 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Tepkinly Evrópusambandið - íslenska - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Æxlishemjandi lyf - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Bupropion Teva Tafla með breyttan losunarhraða 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

bupropion teva tafla með breyttan losunarhraða 150 mg

teva b.v.* - bupropionum hýdróklóríð - tafla með breyttan losunarhraða - 150 mg

Gliolan Evrópusambandið - íslenska - EMA (European Medicines Agency)

gliolan

photonamic gmbh & co. kg - 5-amínólevúlínsýru hýdróklóríð - glioma - Æxlishemjandi lyf - gliolan er ætlað fullorðnum sjúklingum til að visualize illkynja vefjum meðan á aðgerð stendur fyrir illkynja glioma (world health organization iii og iv).

Imbruvica Evrópusambandið - íslenska - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Recarbrio Evrópusambandið - íslenska - EMA (European Medicines Agency)

recarbrio

merck sharp & dohme b.v.  - imipenem einhýdrat, cílastatín járn, relebactam einhýdrat - gramm-neikvæð bakteríusýkingum - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.